Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

1.

Effects of Mirabegron on Anxiety and Depression in Female Patients with Overactive Bladder.

Kinjo M, Yamaguchi T, Tambo M, Okegawa T, Fukuhara H.

Urol Int. 2019;102(3):331-335. doi: 10.1159/000497282. Epub 2019 Feb 21.

PMID:
30799398
2.

Age- and height-adjusted total kidney volume growth rate in autosomal dominant polycystic kidney diseases.

Higashihara E, Yamamoto K, Kaname S, Okegawa T, Tanbo M, Yamaguchi T, Shigemori K, Miyazaki I, Yokoyama K, Nutahara K.

Clin Exp Nephrol. 2019 Jan;23(1):100-111. doi: 10.1007/s10157-018-1617-8. Epub 2018 Jul 26.

3.

Optimal equation for estimation of glomerular filtration rate in autosomal dominant polycystic kidney disease: influence of tolvaptan.

Yamaguchi T, Higashihara E, Okegawa T, Miyazaki I, Nutahara K.

Clin Exp Nephrol. 2018 Oct;22(5):1213-1223. doi: 10.1007/s10157-018-1574-2. Epub 2018 May 22.

PMID:
29789986
4.

Sexual activity and quality of life in Japanese pelvic organ prolapse patients after transvaginal mesh surgery.

Kinjo M, Yoshimura Y, Kitagawa Y, Okegawa T, Nutahara K.

J Obstet Gynaecol Res. 2018 Jul;44(7):1302-1307. doi: 10.1111/jog.13654. Epub 2018 Apr 19.

PMID:
29672997
5.

Vesicoenteric Fistula Arising from an Adenocarcinoma of Ectopic Pancreatic Tissue in a Meckel Diverticulum.

Fujita N, Tambo M, Terado Y, Fujita M, Okegawa T, Nutahara K.

Case Rep Oncol. 2018 Jan 4;11(1):6-10. doi: 10.1159/000485458. eCollection 2018 Jan-Apr.

6.

AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.

Okegawa T, Ninomiya N, Masuda K, Nakamura Y, Tambo M, Nutahara K.

Prostate. 2018 Jun;78(8):576-582. doi: 10.1002/pros.23501. Epub 2018 Mar 5.

PMID:
29508425
7.

Urological laparoendoscopic single-site and reduced port surgery: A nationwide survey in Japan.

Narita M, Kageyama S, Okegawa T, Kinoshita H, Sato F, Nakagawa K, Habuchi T, Hoshi A, Matsubara A, Yoshimura K, Terachi T, Mimata H, Kawauchi A.

Int J Urol. 2018 Mar;25(3):263-268. doi: 10.1111/iju.13504. Epub 2017 Dec 6.

8.

A potentially crucial role of the PKD1 C-terminal tail in renal prognosis.

Higashihara E, Horie S, Kinoshita M, Harris PC, Okegawa T, Tanbo M, Hara H, Yamaguchi T, Shigemori K, Kawano H, Miyazaki I, Kaname S, Nutahara K.

Clin Exp Nephrol. 2018 Apr;22(2):395-404. doi: 10.1007/s10157-017-1477-7. Epub 2017 Oct 5.

9.

Distinguishing testicular torsion from torsion of the appendix testis by clinical features and signs in patients with acute scrotum.

Fujita N, Tambo M, Okegawa T, Higashihara E, Nutahara K.

Res Rep Urol. 2017 Aug 28;9:169-174. doi: 10.2147/RRU.S140361. eCollection 2017.

10.

Intratumor Heterogeneity in Primary Kidney Cancer Revealed by Metabolic Profiling of Multiple Spatially Separated Samples within Tumors.

Okegawa T, Morimoto M, Nishizawa S, Kitazawa S, Honda K, Araki H, Tamura T, Ando A, Satomi Y, Nutahara K, Hara T.

EBioMedicine. 2017 May;19:31-38. doi: 10.1016/j.ebiom.2017.04.009. Epub 2017 Apr 6.

11.

Effectiveness of platinum-based adjuvant chemotherapy for muscle-invasive bladder cancer: A weighted propensity score analysis.

Shimizu F, Muto S, Taguri M, Ieda T, Tsujimura A, Sakamoto Y, Fujita K, Okegawa T, Yamaguchi R, Horie S.

Int J Urol. 2017 May;24(5):367-372. doi: 10.1111/iju.13324. Epub 2017 Mar 9.

13.

Development and Validation of a Novel Recurrence Risk Stratification for Initial Non-muscle Invasive Bladder Cancer in Asia.

Ieda T, Muto S, Shimizu F, Taguri M, Yanada S, Kitamura K, Terai K, Saito K, Ogishima T, Nagata M, Ide H, Okegawa T, Wakumoto Y, Sakamoto Y, Tsujimura A, Yamaguchi R, Nutahara K, Horie S.

EBioMedicine. 2016 Oct;12:98-104. doi: 10.1016/j.ebiom.2016.08.051. Epub 2016 Sep 2.

14.

Laparoendoscopic single-site surgeries: A multicenter experience of 469 cases in Japan.

Sato F, Nakagawa K, Kawauchi A, Matsubara A, Okegawa T, Habuchi T, Yoshimura K, Hoshi A, Kinoshita H, Miyajima A, Naitoh Y, Inoue S, Itaya N, Narita S, Hanai K, Okubo K, Yanishi M, Matsuda T, Terachi T, Mimata H.

Int J Urol. 2017 Jan;24(1):69-74. doi: 10.1111/iju.13235. Epub 2016 Oct 4.

15.

[Usefulness of PSA isoform and related parameter].

Okegawa T.

Nihon Rinsho. 2016 May 20;74 Suppl 3:300-4. Japanese. No abstract available.

PMID:
27344746
16.

Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.

Nakamura Y, Togashi Y, Nakahara H, Tomida S, Banno E, Terashima M, Hayashi H, de Velasco MA, Sakai K, Fujita Y, Okegawa T, Nutahara K, Hamada S, Nishio K.

Mol Cancer Ther. 2016 Aug;15(8):1988-97. doi: 10.1158/1535-7163.MCT-15-0737. Epub 2016 May 20.

17.

[A Case of Atazanavir Urolithiasis Diagnosed by Stone Analysis].

Noma Y, Tambo M, Kitamura J, Okegawa T, Nutahara K.

Hinyokika Kiyo. 2016 Jan;62(1):29-32. Japanese.

18.

Kidney volume estimations with ellipsoid equations by magnetic resonance imaging in autosomal dominant polycystic kidney disease.

Higashihara E, Nutahara K, Okegawa T, Tanbo M, Hara H, Miyazaki I, Kobayasi K, Nitatori T.

Nephron. 2015;129(4):253-62. doi: 10.1159/000381476. Epub 2015 Apr 16.

19.

Clinical efficacy and prognostic factors of tumor progression in Japanese patients with advanced renal cell carcinoma treated with sorafenib.

Kondo T, Nakazawa H, Oya M, Kimura G, Fujii Y, Hatano T, Kawata N, Kume H, Morita M, Nakajima K, Ohno Y, Okegawa T, Takahashi S, Wakumoto Y, Horie S, Yamaguchi R, Saito K, Murakami M.

Jpn J Clin Oncol. 2015 Mar;45(3):274-80. doi: 10.1093/jjco/hyu200. Epub 2014 Nov 23.

PMID:
25420693
20.
21.

Safety study of somatostatin analogue octreotide for autosomal dominant polycystic kidney disease in Japan.

Higashihara E, Nutahara K, Okegawa T, Tanbo M, Mori H, Miyazaki I, Nitatori T, Kobayashi K.

Clin Exp Nephrol. 2015 Aug;19(4):746-52. doi: 10.1007/s10157-014-1047-1. Epub 2014 Oct 29.

PMID:
25351823
22.

Detection and preliminary evaluation of circulating tumor cells in the peripheral blood of patients with eight types of cancer using a telomerase-specific adenovirus.

Yabusaki M, Sato J, Kohyama A, Kojima T, Nobuoka D, Yoshikawa T, Sawada Y, Murakami K, Gohda K, Okegawa T, Nakamura M, Takamatsu K, Ito M, Kaneko K, Nakatsura T.

Oncol Rep. 2014 Nov;32(5):1772-8. doi: 10.3892/or.2014.3436. Epub 2014 Aug 22.

23.

Zoledronic acid improves clinical outcomes in patients with bone metastatic hormone-naïve prostate cancer in a multicenter clinical trial.

Okegawa T, Higaki M, Matsumoto T, Kase H, Murata A, Noda K, Noda H, Asaoka H, Oshi M, Tomoishi J, Uchida H, Higashihara E, Nutahara K; Bone Metastasis Prostate Cancer Group.

Anticancer Res. 2014 Aug;34(8):4415-20.

PMID:
25075079
24.

Serum level and immunohistochemical expression of vascular endothelial growth factor for the prediction of postoperative recurrence in renal cell carcinoma.

Fujita N, Okegawa T, Terado Y, Tambo M, Higashihara E, Nutahara K.

BMC Res Notes. 2014 Jun 17;7:369. doi: 10.1186/1756-0500-7-369.

25.

Development of nomogram to non-steroidal antiandrogen sequential alternation in prostate cancer for predictive model.

Kamiya N, Suzuki H, Nishimura K, Fujii M, Okegawa T, Matsuda T, Morita T, Takihana Y, Ozono S, Namiki M, Matsubara A, Ichikawa T, Miki T.

Jpn J Clin Oncol. 2014 Mar;44(3):263-9. doi: 10.1093/jjco/hyt230. Epub 2014 Feb 9.

PMID:
24516203
26.

Predictors of septic shock in obstructive acute pyelonephritis.

Tambo M, Okegawa T, Shishido T, Higashihara E, Nutahara K.

World J Urol. 2014 Jun;32(3):803-11. doi: 10.1007/s00345-013-1166-4. Epub 2013 Sep 15.

27.

Orphan nuclear receptor HNF4G promotes bladder cancer growth and invasion through the regulation of the hyaluronan synthase 2 gene.

Okegawa T, Ushio K, Imai M, Morimoto M, Hara T.

Oncogenesis. 2013 Jul 29;2:e58. doi: 10.1038/oncsis.2013.25.

28.

Kidney volume and function in autosomal dominant polycystic kidney disease.

Higashihara E, Nutahara K, Okegawa T, Shishido T, Tanbo M, Kobayasi K, Nitadori T.

Clin Exp Nephrol. 2014 Feb;18(1):157-65. doi: 10.1007/s10157-013-0834-4. Epub 2013 Jul 18.

29.

[Predicting postoperative recurrence of renal cell carcinoma using serum vascular endothelial growth factor].

Fujita N, Okegawa T, Tambo M, Shishido T, Nutahara K, Higashihara E.

Nihon Hinyokika Gakkai Zasshi. 2013 Jan;104(1):1-5. Japanese.

PMID:
23457926
30.

Retroperitoneal laparoscopic single-site nephroureterectomy: Initial operative experience.

Okegawa T, Itaya N, Hara H, Nutahara K, Higashihara E.

Asian J Endosc Surg. 2012 Nov;5(4):164-7. doi: 10.1111/j.1758-5910.2012.00146.x. Epub 2012 Jul 17.

PMID:
22805304
31.

Initial operative experience of single-port retroperitoneal laparoscopic nephrectomy.

Okegawa T, Itaya N, Hara H, Nutahara K, Higashihara E.

Int J Urol. 2012 Aug;19(8):778-82. doi: 10.1111/j.1442-2042.2012.03026.x. Epub 2012 Apr 19.

32.

[Usefulness of PSA isoform].

Okegawa T.

Nihon Rinsho. 2011 Jun;69 Suppl 5:254-8. Japanese. No abstract available.

PMID:
22207981
33.

Alternative antiandrogen therapy in patients with castration-resistant prostate cancer: a single-center experience.

Okegawa T, Nutahara K, Higashihara E.

Int J Urol. 2010 Nov;17(11):950-5. doi: 10.1111/j.1442-2042.2010.02620.x.

34.

Effects of eicosapentaenoic acid on biochemical failure after radical prostatectomy for prostate cancer.

Higashihara E, Itomura M, Terachi T, Matsuda T, Kawakita M, Kameyama S, Fuse H, Chiba Y, Hamazaki T, Okegawa T, Tokunaga M, Murota T, Kawa G, Furuya Y, Akashi T, Hamazaki K, Takada H.

In Vivo. 2010 Jul-Aug;24(4):561-5.

PMID:
20668324
35.

[Case of congenital bladder diverticulum--cause of urinary retention in adulthood].

Fujita N, Tambo M, Shishido T, Okegawa T, Nutahara K, Higashihara E.

Nihon Hinyokika Gakkai Zasshi. 2010 May;101(4):619-21. Japanese.

PMID:
20535991
36.

Association of circulating tumor cells with tumor-related methylated DNA in patients with hormone-refractory prostate cancer.

Okegawa T, Nutahara K, Higashihara E.

Int J Urol. 2010 May;17(5):466-75. doi: 10.1111/j.1442-2042.2010.02502.x. Epub 2010 Mar 10.

37.

Immunomagnetic quantification of circulating tumor cells in patients with urothelial cancer.

Okegawa T, Hayashi K, Hara H, Nutahara K, Higashihara E.

Int J Urol. 2010 Mar;17(3):254-8. doi: 10.1111/j.1442-2042.2010.02454.x. Epub 2010 Feb 8.

38.

A pilot study of quality of life of patients with hormone-refractory prostate cancer after gene therapy.

Terao S, Shirakawa T, Acharya B, Miyata M, Hinata N, Tanaka K, Takenaka A, Hara I, Naoe M, Fuji K, Okegawa T, Higashihara E, Kamidono S, Fujisawa M, Gotoh A.

Anticancer Res. 2009 May;29(5):1533-7.

39.

Comparison of serum HER2/neu with immunohistochemical HER2/neu expression for the prediction of biochemical progression in metastatic prostate cancer.

Tambo M, Higashihara E, Terado Y, Nutahara K, Okegawa T.

Int J Urol. 2009 Apr;16(4):369-74. doi: 10.1111/j.1442-2042.2009.02253.x. Epub 2009 Feb 15.

40.

Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer.

Okegawa T, Nutahara K, Higashihara E.

J Urol. 2009 Mar;181(3):1091-7. doi: 10.1016/j.juro.2008.11.015. Epub 2009 Jan 16.

PMID:
19150091
41.

Comparison of transperitoneal and retroperitoneal laparoscopic nephrectomy for renal cell carcinoma: a single-center experience of 100 cases.

Okegawa T, Noda H, Horie S, Nutahara K, Higashihara E.

Int J Urol. 2008 Oct;15(11):957-60. doi: 10.1111/j.1442-2042.2008.02132.x. Epub 2008 Sep 2.

42.

Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.

Okegawa T, Nutahara K, Higashihara E.

J Urol. 2008 Oct;180(4):1342-7. doi: 10.1016/j.juro.2008.06.021. Epub 2008 Aug 15.

PMID:
18707699
43.

[Comparison of clinical results between TUR-P and holmium laser enucleation of the prostate (HoLEP) based on the initial experience].

Shishido T, Enomoto K, Fujita N, Suzuki A, Hayashi K, Nomura M, Itaya N, Tanbo M, Watanabe K, Noda H, Okegawa T, Nutahara K, Higashihara E.

Nihon Hinyokika Gakkai Zasshi. 2008 Mar;99(3):543-50. Japanese.

44.

Serum level of macrophage colony-stimulating factor is increased in prostate cancer patients with bone metastasis.

Ide H, Hatake K, Terado Y, Tsukino H, Okegawa T, Nutahara K, Higashihara E, Horie S.

Hum Cell. 2008 Feb;21(1):1-6. doi: 10.1111/j.1749-0774.2007.00042.x.

PMID:
18190394
45.

Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer.

Shirakawa T, Terao S, Hinata N, Tanaka K, Takenaka A, Hara I, Sugimura K, Matsuo M, Hamada K, Fuji K, Okegawa T, Higashihara E, Gardner TA, Kao C, Chung LW, Kamidono S, Fujisawa M, Gotoh A.

Hum Gene Ther. 2007 Dec;18(12):1225-32.

PMID:
18021019
46.

Site-specific, covalent attachment of poly(dT)-modified peptides to solid surfaces for microarrays.

Kimura N, Okegawa T, Yamazaki K, Matsuoka K.

Bioconjug Chem. 2007 Nov-Dec;18(6):1778-85. Epub 2007 Oct 23.

PMID:
17953441
47.

Prostatic cyst arising around the bladder neck-cause of bladder outlet obstruction: two case reports.

Tambo M, Okegawa T, Nutahara K, Higashihara E.

Hinyokika Kiyo. 2007 Jun;53(6):401-4.

48.

A histone deacetylase inhibitor enhances adenoviral infection of renal cancer cells.

Okegawa T, Sayne JR, Nutahara K, Pong RC, Saboorian H, Kabbani W, Higashihara E, Hsieh JT.

J Urol. 2007 Mar;177(3):1148-56.

PMID:
17296436
49.

Laparoscopic management of urachal remnants in adulthood.

Okegawa T, Odagane A, Nutahara K, Higashihara E.

Int J Urol. 2006 Dec;13(12):1466-9.

50.

Supplemental Content

Loading ...
Support Center